ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, heart failure

Polypharmacy icon of two pills

Study population:

Patients with heart failure

(NYHA class I - IV) due to left ventricular systolic dysfunction (ejection fraction ≤0.35).

Comments:

Mean age of patients was 61 years, approximately 80% were male. Less than 2% were NYHA Class IV.

Treatment also reduced hospital admissions for heart failure.

Mortality benefit appears to be most marked in the first 24 months of treatment.

 

Outcome Duration NNT Annualised NNT
Prevent one death (any cause) 41.4 months

22

76

References

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The New England Journal of Medicine 1991; 325(5): 293-302